Mission Therapeutics’ highlights positive Parkinson’s Disease USP30 target and inhibitor data


15-11-2017

Mission Therapeutics is presenting two posters with new research and preclinical data from its USP30 inhibitor Parkinson’s disease programmes today at Neuroscience 2017, the 47th Annual Meeting of the Society for Neuroscience, in Washington, DC. The meeting is the world’s largest neuroscience conference.

USP30 is a mitochondrial-associated DUB that has emerged as a promising new target in Parkinson’s disease. It has been implicated in the control of mitophagy, a cellular mitochondrial quality control mechanism. This process regulates the selective clearance of poorly functioning mitochondria by modifying levels of a protein called ubiquitin.

Failure of mitochondrial quality control results in the accumulation of dysfunctional energy-producing mitochondria, which causes oxidative stress. This stress eventually leads to a pathological mechanism that can result in Parkinson’s disease, and involves the degeneration of the highly-active substantia nigra neurons in the brain. Mission Therapeutics is developing potent and selective inhibitors against USP30 which can help improve mitochondrial quality control, with the aim of halting or slowing down the development of Parkinson’s.

Dr Anker Lundemose, Chief Executive Officer of Mission Therapeutics, said:

“DUBs are playing an emerging role as targets across a number of serious diseases, as highlighted in our team’s recently-published Nature Reviews Drug Discovery paper. The data from the studies presented at this conference further enhances our understanding of the cellular mechanisms of USP30 and the significance of inhibiting this particular DUB in Parkinson’s disease. Our research is also providing invaluable information that is helping to shape our preclinical development strategy.”

Details of Poster Presentations:

Poster# 759.03/Title: USP30 inhibitors for Parkinson’s Disease

Poster# 759.04/Title: Targeting USP30 in Parkinson’s iPSC-derived dopamine neurons

Session Title: The Pathogenesis Mechanisms of Mitochondria in Parkinson’s Disease

Session Number: 759

Session Time: Wednesday November 15, 2017 1.00 pm – 5:00 pm ET

The meeting will be attended by two scientists from Mission Therapeutics’ CNS team: Dr Paul Thompson, Medical Director, CNS Translational Medicine and Dr Marc Watson. Principal Scientist, CNS.

To read more information, click here.

MISSION Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.

MISSION Therapeutics